Pacific Biosciences Of California (PACB) Net Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.27% |
| Dec 31, 2025 | -20.48% |
| Sep 30, 2025 | -9.89% |
| Jun 30, 2025 | -12.25% |
| Mar 31, 2025 | -66.82% |
| Dec 31, 2024 | 16.30% |
| Sep 30, 2024 | -16.11% |
| Jun 30, 2024 | -47.26% |
| Mar 31, 2024 | -20.51% |
| Dec 31, 2023 | -21.29% |
| Sep 30, 2023 | -21.47% |
| Jun 30, 2023 | -25.60% |
| Mar 31, 2023 | -29.11% |
| Dec 31, 2022 | -31.88% |
| Sep 30, 2022 | -28.23% |
| Jun 30, 2022 | -23.14% |
| Mar 31, 2022 | -27.55% |
| Dec 31, 2021 | -29.94% |
| Jun 30, 2021 | -16.89% |
| Mar 31, 2021 | -12.91% |
| Dec 31, 2020 | 112.01% |
| Sep 30, 2020 | -71.09% |
| Jun 30, 2020 | -14.27% |
| Mar 31, 2020 | -10.49% |
| Dec 31, 2019 | 0.03% |
| Sep 30, 2019 | -25.81% |
| Jun 30, 2019 | -5.66% |
| Mar 31, 2019 | -10.19% |
| Dec 31, 2018 | -12.05% |
| Sep 30, 2018 | -4.16% |
| Jun 30, 2018 | -1.57% |
| Mar 31, 2018 | -3.12% |
| Dec 31, 2017 | 0.57% |
| Sep 30, 2017 | 0.40% |
| Jun 30, 2017 | -2.19% |
| Mar 31, 2017 | 2.58% |
| Dec 31, 2016 | 3.78% |
| Sep 30, 2016 | 9.82% |
| Jun 30, 2016 | 3.60% |
| Mar 31, 2016 | 11.17% |
| Dec 31, 2015 | 45.04% |
| Sep 30, 2015 | 15.39% |
| Jun 30, 2015 | 18.06% |